Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
an alternative funded GLP-1 receptor agonist As a result of global supply issues with dulaglutide, Pharmac funded an alternative GLP-1 receptor agonist, liraglutide, with Special Authority approval from March, 2023
Format & Delivery: This will be delivered via a zip folder
Glucagon-like Peptide 1 (GLP-1) Analogues Market Overview Glucagon-like Peptide 1 (GLP-1) Analogues Market reached US$ 62.81 Billion in 2024 and is expected to reach US$ 299.08 Billion by 2033 , growing at a CAGR of 17.6 % during the forecast period 2026-2033
Marketed as Mounjaro for diabetes and Zepbound for weight management, tirzepatide has rapidly become one of the most prescribed medications in the diabetes and obesity space
GLP-1 receptor agonist as adjuvant therapy in Type 1 diabetes: No apparent benefit for Beta-Cell function or glycemia
US$ 23.22
US$ 26.23
US$ 27.82
US$ 26.46
US$ 27.28
US$ 28.08
US$ 22.19
US$ 24.87
US$ 26.67
US$ 23.07
US$ 27.51
